证券代码：300142 证券简称：沃森生物 公告编号：2025-026 1、2025年4月12日，云南沃森生物技术股份有限公司（以下简称"公司"） 董事会以公告形式通知召开2024年年度股东大会。关于召开2024年年度股东大会 的提示性公告已于2025年4月30日以公告的形式发出。 云南沃森生物技术股份有限公司 2024年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会未涉及变更以往股东大会决议。 3、本次股东大会采用现场会议与网络投票相结合的方式召开。 一、会议召开和出席情况 2、会议召开方式：采用现场会议与网络投票相结合的方式。 3、会议召开日期和时间： 现场会议召开日期和时间：2025年5月8日（星期四）下午14:00； 网络投票日期和时间：2025年5月8日。其中，通过深圳证券交易所交易系统 进行投票的时间为2025年5月8日上午9:15-9:25、9:30-11:30，下午13:00-15:00；通 过深圳证券交易所互联网投票系统进行投票的时间为2025年5月8 ...

北京市竞天公诚（深圳）律师事务所 关于云南沃森生物技术股份有限公司 深圳市南山区前海大道前海嘉里商务中心 T2 栋 1401A 室 邮编：518054 电话：(86-755) 21557000 传真：(86-755) 2155 7099 2024 年年度股东大会的 法律意见书 致：云南沃森生物技术股份有限公司（贵公司） 北京市竞天公诚（深圳）律师事务所（以下简称"本所"）接受贵公司的委 托，指派律师出席并见证贵公司 2024 年年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称《公司法》）、《中华 人民共和国证券法》（以下简称《证券法》）、《上市公司股东会规则》（以下 简称《股东会规则》）、《律师事务所从事证券法律业务管理办法》（以下简称 《证券法律业务管理办法》）、《律师事务所证券法律业务执业规则（试行）》 （以下简称《证券法律业务执业规则》）等相关法律、行政法规、规章、规范性 文件及《云南沃森生物技术股份有限公司章程》（以下简称《公司章程》）的规 定，就本次会议的召集与召开程序、召集人资格、出席会议人员资格、会议表决 程序及表决结果等事宜，出具本法律意见书。 对本法律意 ...

Core Points - Watson Bio reported a significant decline in financial performance for 2024, with total revenue of 2.82 billion yuan, a decrease of 31.41% year-on-year, and a net profit of 142.16 million yuan, down 66.10% from the previous year [1][2] Financial Performance - Total revenue for 2024 was 2,821,441,302.71 yuan, compared to 4,113,772,327.17 yuan in 2023, marking a 31.41% decrease [2] - Net profit attributable to shareholders was 142,160,410.01 yuan, down from 419,390,211.20 yuan in 2023, a decline of 66.10% [2] - Net profit after deducting non-recurring gains and losses was 108,396,074.77 yuan, a decrease of 81.10% from 573,585,030.87 yuan in 2023 [2] - Operating cash flow for 2024 was 1,036,524,527.50 yuan, down 8.58% from 1,133,768,797.73 yuan in 2023 [2] - Basic earnings per share were 0.0889 yuan, a decrease of 66.08% from 0.2621 yuan in 2023 [2] - Total assets at the end of 2024 were 14,724,311,909.25 yuan, down 5.55% from 15,588,869,273.40 yuan at the end of 2023 [2] Operational Challenges - The decline in net profit was attributed to reduced domestic sales revenue due to changes in population structure and increased market competition, as well as a decrease in the bidding price of the bivalent HPV vaccine [1][2] - Sales in the self-paid market for the HPV vaccine were under pressure due to reduced willingness for self-paid vaccinations and the expansion of the nine-valent HPV vaccine age range [1][2] Research and Development - R&D expenses for 2024 were 597 million yuan, a decrease of 23.17% year-on-year [3][4] - The number of R&D personnel decreased to 172, down 20.37% from 216 in 2023, representing 8.90% of total employees [3][4] Leadership and Compensation - The chairman of Watson Bio, Li Yunchun, has extensive experience in the vaccine industry and has held various leadership roles [5] - Li Yunchun's compensation for 2024 was 2.842 million yuan, a decrease of 34.44% compared to 4.328 million yuan in 2023 [6][7]

沃森生物（300142）公告，2025年4月30日，公司董事会收到董事黄镇先生的书面辞职报告。黄镇先生 因个人原因辞去公司第五届董事会董事职务，辞职自报告送达董事会时生效。黄镇先生不再担任公司及 子公司其他职务。截至公告披露日，黄镇先生持有公司股份1769.87万股。黄镇先生辞职不会导致董事 会成员低于法定最低人数，不会对公司董事会的正常运作产生重大影响。 ...

特此公告。 云南沃森生物技术股份有限公司 董事会 2025 年 4 月 30 日，云南沃森生物技术股份有限公司（以下简称"公司"） 董事会收到董事黄镇先生提交的书面辞职报告。黄镇先生因个人原因提请辞去其 所担任的公司第五届董事会董事职务。本次辞去相关职务后，黄镇先生不再担任 公司及子公司其他职务。 黄镇先生担任公司董事的原定任期至 2025 年 10 月 12 日为止。根据《中华 人民共和国公司法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》和《公司章程》的有关规定，黄镇先生本次辞职自其书面辞 职报告送达董事会时生效。黄镇先生的辞职不会导致公司董事会成员低于法定最 低人数，不会对公司董事会的正常运作产生重大影响。 截至本公告披露日，黄镇先生持有公司股份 17,698,729 股。黄镇先生辞职后 将继续严格遵守《中华人民共和国证券法》《上市公司股东减持股份管理暂行办 法》《上市公司董事和高级管理人员所持本公司股份及其变动管理规则》《深圳证 券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《深圳证 券交易所上市公司自律监管指引第 18 号——股东及董事、高级管理人 ...

证券代码：300142 证券简称：沃森生物 公告编号：2025-024 1、股东大会届次：云南沃森生物技术股份有限公司2024年年度股东大会 2、会议召集人：公司董事会。 3、会议召开的合法、合规性：经公司第五届董事会第二十六次会议审议通 过，决定召开2024年年度股东大会，召集程序符合有关法律、行政法规、部门规 章、规范性文件和公司章程的规定。 4、会议召开日期和时间： 现场会议召开日期和时间：2025年5月8日（星期四）下午14:00； 云南沃森生物技术股份有限公司 关于召开2024年年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 经云南沃森生物技术股份有限公司（以下简称"公司"）第五届董事会第二 十六次会议审议通过，决定于2025年5月8日（星期四）召开公司2024年年度股东 大会。本次股东大会的会议通知已于2025年4月12日公布于中国证监会指定的创 业板信息披露网站巨潮资讯网。本次股东大会将采用现场会议与网络投票相结合 的方式召开。现就本次股东大会的相关事宜再次提示公告如下： 一、召开会议的基本情况 网络投票日期和时间：20 ...

Core Viewpoint - The performance of several vaccine companies in China is significantly declining in 2024 due to industry policy adjustments, decreased public willingness to vaccinate, and changing market demands, leading to a challenging environment for the industry [1] Financial Performance - The average revenue of vaccine companies in 2024 is 7.131 billion yuan, down 21.63% from 9.099 billion yuan in 2023, while the average net profit is 788 million yuan, a decrease of 35.60% from 1.222 billion yuan in 2023 [1] - Companies like Zhifei Biological, Wantai Biological, and Hualan Biological reported revenue declines exceeding 50%, while Watson Biological, Baike Biological, and Jindike saw declines of over 30% [1] - Kangxino's revenue increased by over 130% due to its quadrivalent meningococcal conjugate vaccine, benefiting from the resolution of global public health events [1] Price Competition Impact - The price war among vaccine products, particularly HPV, influenza, and pneumonia vaccines, has severely impacted net profits, with Wantai Biological, Kangtai Biological, Hualan Biological, and Zhifei Biological experiencing declines of 91.49%, 76.59%, 76.10%, and 74.99% respectively [2] - Wantai Biological's revenue for 2024 is 2.245 billion yuan, down 59.25%, and its net profit is 106 million yuan, down 91.49% [6] - Watson Biological's revenue is 2.821 billion yuan, a decline of 31.41%, with a net profit of 142 million yuan, down 66.10% [6] Market Dynamics - The domestic vaccine market is becoming increasingly competitive, with many companies focusing on traditional products and facing challenges from product homogeneity and market saturation [3] - The overall vaccination rate in China is low, with only about 3% for influenza vaccines, indicating significant growth potential in the market despite current pressures [7] R&D and Innovation - Companies are increasing R&D investments, with Zhifei Biological investing 1.391 billion yuan in 2024, and several companies allocating over 20% of their revenue to R&D [8] - New vaccine technologies, including mRNA and DNA vaccines, are emerging, which could lead to breakthroughs in disease prevention and treatment [9] International Expansion - Many vaccine companies are pursuing international markets, with Kangxino and Baike Biological successfully exporting products to various countries [10][11] - Watson Biological reported overseas revenue of 570 million yuan in 2024, a year-on-year increase of approximately 98% [11] - The global human vaccine market is projected to grow significantly, with emerging markets providing opportunities for Chinese vaccine companies due to their competitive pricing [12][13]

以下文章来源于MedTrend医趋势 ，作者更多精彩资讯 MedTrend医趋势 . 关注我们，带你洞见医疗的未来！MedTrend医趋势——专注于医疗医药、生命科学、医院领域，为您 提供及时、实用的热点资讯、市场概况、行业趋势等精彩内容，旨在建设全面、周到、专业的信息分享 与交流平台。 作者 | MedTrend医趋势 来源 | MedTrend医趋势 导语 ：没有任何一个赛道能逃过中国的内卷。 默沙东应该急了。 4月24日，默沙东公布2025 Q1业绩，总体营收小幅下锉，主要原因是两大支柱产品全球药王K药和 HPV疫苗佳达修（Gardasil/Gardasil 9）都未及销售预期。 另外两个数字则惨烈得多——佳达修Q1销售额仅为13.27亿美元，同比大幅下滑41%；其中，默沙 东中国区收入同比下滑62%至6.68亿美元，在默沙东全球的业务份额降至不足5%，跌幅远超公司平 均水平。 | | 2025 | | | 2024 | | | % Change | | --- | --- | --- | --- | --- | --- | --- | --- | | | 10 | 10 | 20 | 3Q | 40 ...

Investment Rating - The report does not explicitly state an investment rating for the industry, but it suggests a long-term focus on domestic innovative drugs in the oncology field and AI medical investment opportunities [3][4]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.16%, outperforming the Wind All A index (1.15%) and the CSI 300 index (0.38%) [3][8]. - The upcoming ASCO conference is highlighted as a significant event for domestic innovative drug companies, with over 70 oral presentations and more than 10 major studies expected [3][4]. - The Ministry of Industry and Information Technology and six other departments issued a plan for the digital transformation of the pharmaceutical industry, aiming for significant advancements by 2027 and full coverage by 2030 [3][4]. Market Weekly Review - The pharmaceutical and biotechnology sector increased by 1.16% from April 21 to April 25, outperforming the Wind All A index and the CSI 300 index [3][8]. - Notable performers included medical research outsourcing (6.34%) and raw materials (4.72%), while blood products (-3.26%) and vaccines (-6.38%) continued to decline [3][9]. - Individual stock performances showed significant gains for Yong'an Pharmaceutical (31.4%), Shuyou Shen (28.4%), and Erkang Pharmaceutical (27.7%), while *ST Jiyuan (-43.2%), Nanhua Biological (-35.3%), and Shuangcheng Pharmaceutical (-27.7%) faced substantial losses [3][11]. Industry News and Key Company Announcements - On April 25, Kangfang Bio announced FDA approval for its drug Anike for the treatment of recurrent or metastatic nasopharyngeal carcinoma [12]. - The same day, Kangfang Bio also reported the approval of its PD-1/VEGF bispecific antibody for first-line treatment of specific lung cancer types [13]. - The digital transformation plan for the pharmaceutical industry aims to enhance competitiveness and quality management through AI and data integration by 2030 [3][4].

二、监事会会议审议情况 证券代码：300142 证券简称：沃森生物 公告编号：2025-020 云南沃森生物技术股份有限公司 第五届监事会第二十次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 云南沃森生物技术股份有限公司（以下简称"公司"）第五届监事会第二十 次会议于 2025 年 4 月 24 日以现场会议的方式在公司会议室召开，会议通知于 4 月 19 日以电子邮件方式发出。本次会议应参会监事 3 人，实际参加会议监事 3 人。会议由监事会主席丁世青女士主持。本次会议的召集、召开符合《公司法》 及《公司章程》的规定。 1、审议通过了《关于<2025 年第一季度报告>的议案》 监事会对公司《2025 年第一季度报告》审核后，发表审核意见如下：董事 会编制和审议公司《2025 年第一季度报告》的程序符合法律、行政法规和中国 证监会的规定；公司《2025 年第一季度报告》的内容和格式符合中国证监会和 深圳证券交易所的规定；报告内容真实、准确、完整地反映了公司报告期内的实 际情况，不存在任何虚假记载、误导性陈述或重大遗漏。 ...